Company Overview - Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals and associated medical technologies [5] - The company is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan [5] - Telix aims to address significant unmet medical needs in oncology and rare diseases through its portfolio of clinical and commercial stage products [5] Investor Day Announcement - Telix will host an Investor Day on June 11, 2025, in New York City, focusing on growth opportunities in its commercial and clinical portfolio [1][2] - The event will feature presentations from key members of the Telix leadership team, including the Managing Director and Group CEO, Dr. Christian Behrenbruch, and other executives [3] - Key Opinion Leaders will also share insights on the clinical utility and opportunities for Telix's theranostic candidates during the event [3] Attendance Information - Attendance at the Investor Day is by invitation only for qualified institutional investors and analysts, and advance registration is required [4][5]
Telix to Host Investor Day in New York City on June 11, 2025